Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study.
Ageusia
Anosmia
COVID-19
Fatigue
Long COVID
Long-term health consequences
PCS
Post infectious syndrome
Post-COVID syndrome
SARS-CoV-2
Shortness of breath
Journal
The Lancet regional health. Europe
ISSN: 2666-7762
Titre abrégé: Lancet Reg Health Eur
Pays: England
ID NLM: 101777707
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
entrez:
24
5
2021
pubmed:
25
5
2021
medline:
25
5
2021
Statut:
ppublish
Résumé
While the leading symptoms during coronavirus disease 2019 (COVID-19) are acute and the majority of patients fully recover, a significant fraction of patients now increasingly experience long-term health consequences. However, most data available focus on health-related events after severe infection and hospitalisation. We present a longitudinal, prospective analysis of health consequences in patients who initially presented with no or minor symptoms of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. Hence, we focus on mild COVID-19 in non-hospitalised patients. 958 Patients with confirmed SARS-CoV-2 infection were observed from April 6th to December 2nd 2020 for long-term symptoms and SARS-CoV-2 antibodies. We identified anosmia, ageusia, fatigue or shortness of breath as most common, persisting symptoms at month 4 and 7 and summarised presence of such long-term health consequences as post-COVID syndrome (PCS). Predictors of long-term symptoms were assessed using an uni- and multivariable logistic regression model. We observed 442 and 353 patients over four and seven months after symptom onset, respectively. Four months post SARS-CoV-2 infection, 8•6% (38/442) of patients presented with shortness of breath, 12•4% (55/442) with anosmia, 11•1% (49/442) with ageusia and 9•7% (43/442) with fatigue. At least one of these characteristic symptoms was present in 27•8% (123/442) and 34•8% (123/353) at month 4 and 7 post-infection, respectively. A lower baseline level of SARS-CoV-2 IgG, anosmia and diarrhoea during acute COVID-19 were associated with higher risk to develop long-term symptoms. The on-going presence of either shortness of breath, anosmia, ageusia or fatigue as long-lasting symptoms even in non-hospitalised patients was observed at four and seven months post-infection and summarised as post-COVID syndrome (PCS). The continued assessment of patients with PCS will become a major task to define and mitigate the socioeconomic and medical long-term effects of COVID-19. COVIM:"NaFoUniMedCovid19"(FKZ: 01KX2021).
Sections du résumé
BACKGROUND
BACKGROUND
While the leading symptoms during coronavirus disease 2019 (COVID-19) are acute and the majority of patients fully recover, a significant fraction of patients now increasingly experience long-term health consequences. However, most data available focus on health-related events after severe infection and hospitalisation. We present a longitudinal, prospective analysis of health consequences in patients who initially presented with no or minor symptoms of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. Hence, we focus on mild COVID-19 in non-hospitalised patients.
METHODS
METHODS
958 Patients with confirmed SARS-CoV-2 infection were observed from April 6th to December 2nd 2020 for long-term symptoms and SARS-CoV-2 antibodies. We identified anosmia, ageusia, fatigue or shortness of breath as most common, persisting symptoms at month 4 and 7 and summarised presence of such long-term health consequences as post-COVID syndrome (PCS). Predictors of long-term symptoms were assessed using an uni- and multivariable logistic regression model.
FINDINGS
RESULTS
We observed 442 and 353 patients over four and seven months after symptom onset, respectively. Four months post SARS-CoV-2 infection, 8•6% (38/442) of patients presented with shortness of breath, 12•4% (55/442) with anosmia, 11•1% (49/442) with ageusia and 9•7% (43/442) with fatigue. At least one of these characteristic symptoms was present in 27•8% (123/442) and 34•8% (123/353) at month 4 and 7 post-infection, respectively. A lower baseline level of SARS-CoV-2 IgG, anosmia and diarrhoea during acute COVID-19 were associated with higher risk to develop long-term symptoms.
INTERPRETATION
CONCLUSIONS
The on-going presence of either shortness of breath, anosmia, ageusia or fatigue as long-lasting symptoms even in non-hospitalised patients was observed at four and seven months post-infection and summarised as post-COVID syndrome (PCS). The continued assessment of patients with PCS will become a major task to define and mitigate the socioeconomic and medical long-term effects of COVID-19.
FUNDING
BACKGROUND
COVIM:"NaFoUniMedCovid19"(FKZ: 01KX2021).
Identifiants
pubmed: 34027514
doi: 10.1016/j.lanepe.2021.100122
pii: S2666-7762(21)00099-5
pmc: PMC8129613
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100122Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors have nothing to disclose.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
BMC Public Health. 2021 Aug 16;21(1):1554
pubmed: 34399729
EClinicalMedicine. 2020 Dec;29:100630
pubmed: 33200120
J Korean Med Sci. 2020 May 11;35(18):e174
pubmed: 32383370
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261
pubmed: 32253535
Intensive Care Med. 2020 Nov;46(11):2035-2047
pubmed: 33034689
J Intern Med. 2021 Aug;290(2):451-461
pubmed: 33403772
Nephrologe. 2020 Dec 15;:1-7
pubmed: 33343742
J Intern Med. 2020 Sep;288(3):335-344
pubmed: 32352202
BMJ. 2006 Sep 16;333(7568):575
pubmed: 16950834
Clin Exp Med. 2020 Nov;20(4):493-506
pubmed: 32720223
PLoS One. 2020 Nov 9;15(11):e0240784
pubmed: 33166287
Arch Intern Med. 2009 Dec 14;169(22):2142-7
pubmed: 20008700
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Thorax. 2021 Apr;76(4):396-398
pubmed: 33172844
Clin Infect Dis. 2020 Nov 19;71(16):2262-2264
pubmed: 32357210
J Med Virol. 2021 May;93(5):2555-2556
pubmed: 33095459
JAMA Neurol. 2021 Jun 1;78(6):760-762
pubmed: 33576767
Clin Microbiol Infect. 2021 Feb;27(2):258-263
pubmed: 33031948
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Respir Res. 2020 Feb 11;21(1):49
pubmed: 32046720
Nature. 2020 Sep;585(7825):339-341
pubmed: 32929257
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Eur Respir J. 2012 Jul;40(1):255-63
pubmed: 22441750
PLoS One. 2020 Oct 21;15(10):e0241104
pubmed: 33085715
Ann Intern Med. 2021 Apr;174(4):576-578
pubmed: 33175566
J Gen Intern Med. 2001 Apr;16(4):266-75
pubmed: 11318929
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Viruses. 2020 Sep 18;12(9):
pubmed: 32962125
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Nat Rev Neurol. 2015 Aug;11(8):446-56
pubmed: 26215621
Nat Rev Immunol. 2014 Oct;14(10):667-85
pubmed: 25234148
ERJ Open Res. 2020 Oct 26;6(4):
pubmed: 33257910
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
PLoS One. 2020 Oct 9;15(10):e0240502
pubmed: 33035234